Article info

Market competition among manufacturers of novel high-risk therapeutic devices receiving FDA premarket approval between 2001 and 2018

Authors

  • Vinay K Rathi Department of Otolaryngology – Head and Neck Surgery, Massachusetts Eye and Ear, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • James L Johnston Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Sanket Dhruva Department of Medicine, University of California San Francisco School of Medicine, San Francisco, California, USASan Francisco Veterans Affairs Health Care System, San Fransisco, California, USA PubMed articlesGoogle scholar articles
  • Joseph Ross Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USACenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, USADepartment of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, USAYale National Clinician Scholars Program, Yale School of Medicine, New Haven, Connecticut, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Vinay K Rathi; vinay_rathi{at}meei.harvard.edu

Citation

Rathi VK, Johnston JL, Dhruva S, et al
Market competition among manufacturers of novel high-risk therapeutic devices receiving FDA premarket approval between 2001 and 2018

Publication history

  • First published February 8, 2023.
Online issue publication 
February 08, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.